Presentation is loading. Please wait.

Presentation is loading. Please wait.

Healthcare-Associated Infections and Infection Control

Similar presentations


Presentation on theme: "Healthcare-Associated Infections and Infection Control"— Presentation transcript:

1 Healthcare-Associated Infections and Infection Control
Timothy H. Dellit, MD Medical Director, Infection Control Harborview Medical Center

2 Patient Safety and Infection Control
Prevention, monitoring, and feedback Healthcare-associated infections Catheter-associated bloodstream infections Ventilator-associated pneumonia Surgical site infections Catheter-associated UTI Transmission of multidrug-resistant/marker organisms MRSA VRE Carbapenem-resistant Acinetobacter ESBL-producing organisms → MDR Enterobacteriaceae C. difficile Aspergillus in burn and immunocompromised populations Tuberculosis

3 Increasing Regulation and Reporting
CMS and “medical errors” FY2008 Catheter-associated urinary tract infection Vascular catheter-associated infections Mediastinitis after CABG FY2009 SSI following select orthopedic procedures Spinal fusion Elbow and shoulder arthroplasty SSI following bariatric surgery Mandatory reporting of healthcare-associated infections (HB 1106) Central line infections in ICU: July 2008 Ventilator-associated pneumonia: January 2009 Selected surgical site infections: January 2010 Cardiac surgery Total hip and knee arthroplasty Hysterectomy Not selected VAP S. aureus septicemia/ MRSA C. difficile Legionnaires’

4

5

6 “MDRO Bundle” Hand Hygiene Contact precautions
Minimize shared equipment Environmental cleaning Healthcare-associated infections preventive bundles Catheter-associated BSI Ventilator-associated pneumonia Catheter-associated UTI SCIP measures Active surveillance cultures Chlorhexidine baths Antimicrobial stewardship Lancet 2000;356:

7

8 Role of Environmental Contamination
Contact Contamination Percent positive Percent of Surfaces Positive for MRSA Infect Control Hosp Epidemiol 1997;18:

9 To Survey or Not to Survey?
Surveillance Cultures Reduce MRSA Bacteremia Interventions over 9 yr Sterile CVC placement Alcohol-based hand hygiene Hand hygiene campaign ICU surveillance for MRSA (16 months) 29% of newly detected MRSA carriers develop infection within 18 months 75% 67% Incidence density per 1000 pt-days 40% Reduced ICU transmission by 47% 43 vs. 23 cases per 1000 at risk patients Clin Infect Dis 2003;36:281-5 Clin Infect Dis 2006;43:971-8

10 Chlorhexidine Body Wash in the ICU
Decreased Acquisition of VRE Before and after, compared with soap and water Decreased Bloodstream Infections Cross-over, compared with soap and water 6.4 vs BSI per 1000 catheter-days Arch Intern med 2007;167: Arch Intern Med 2006; 166:306-12

11 HMC Nosocomial MRSA Rates Quarterly
Number of Cases 2007: 331 Cases 2008: 268 Cases 2009: 154 Cases Source: Infection Control, for more information, please contact Dr. Tim Dellit, Confidential QI

12 Central Line-Associated BSI
ICU CVC utilization 0.39 – 0.71 catheters/pt 15 million catheter-days per year in US ICU rate 1.3 to 5.5 per 1000 catheter-days (NHSN mean) 80,000 CR-BSI annually in US ICUs Attributable mortality 0-35% Healthcare cost $296 million to $2.3 billion Attributable cost $15,000-$56,000 Prolonged ICU and hospital LOS Clin Infect Dis 2002;35: Am J Infect Control 2009;37:

13 NHSN CLA-BSI Pathogens
Pathogen (%) (%) (%) Coag-negative staphylococci Staphylococcus aureus * Enterococcus Candida sp Enterobacter Pseudomonas aeruginosa Klebsiella pneumoniae E. Coli Clin Infect Dis 2002;35: Infect Control Hosp Epidemiol 2008;29: *MRSA 5.6%, MSSA 4.3%

14 Prevention of Catheter-Associated BSI
IHI “Central Line Bundle” Hand hygiene Chlorhexidine skin prep Maximal barriers Full drape Mask, hair cover, sterile gown, sterile gloves Optimal catheter site selection Daily review of line necessity Implementation AND documentation Institute for Healthcare Improvement

15 Median Bloodstream Infections per 1000 Catheter-Days
Bundle in Action Median Bloodstream Infections per 1000 Catheter-Days Months After Implementation Reduction in mean rate from 7.7 to 1.4 per 1000 catheter-days N Engl J Med 2006;355:

16 UHC Benchmark of Key Performance Measures
There is work to be done! Key Performance Measure Hospital Performance Patient Level % of cases median range Central Venous Catheter Placed in the Subclavian Vein 44.2% 14.3 – 73.3% Evidence of Maximal Barrier Precautions for Insertion 0.0% 0.0 – 8.2% Hand Washing 0.0 – 39.0% Full Body Drape 3.0% 0.0 – 46.3% Sterile Gloves and Gown 1.9% Cap and Mask 0.0 – 13.6% Chlorhexidine Skin Prep for Insertion 0.0 – 98.1% Daily Dressing Inspection 97.5% 25.1 – 100% Daily Assessment of Medical Necessity to Continue CVC 16.4% 0.0 – 100% Operational Yes % (n) Site # Best Practice* CVC Insertion Policy 11.8% (2) 29, 89 Mandated Use of a CVC Insertion Checklist 84, 87 UHC’s MVP Bundle of Care Interventions Infect Control Hosp Epidemiol 2008;29:440-2

17 National Reduction in CLA-BSI
JAMA 2009;301:727-36

18 MRSA Central Line-Associate BSI
50% reduction in MRSA CLA-BSI (0.43 vs 0.21 per 1000 catheter-days) JAMA 2009;301:727-36

19 Hospital-Acquired UTI
• 40% of healthcare-associated infections • 80% due to indwelling urethral catheter Survey of Hospital Monitoring Potential Strategies Insertion/care • Catheter reminders/ automatic stop orders • Bladder US scanners • Condom catheters • Antimicrobial catheters No monitoring (%) Clin Infect Dis 2008;46:243-50 Aymptomatic bacteriuria vs. Symptomatic UTI in patients without localizing GU symptoms

20 CA-UTI Pathogens NHSN 2006-2007
Infect Control Hosp Epidemiol 2008;29:

21 Catheter-Associated UTI
Duration of catheterization is primary risk Providers unaware of catheter status Students 21% Interns 22% Residents 27% Attendings 38% Daily assessment of need, especially when transferred from ICU to floor Am J Med 2000;109:476-80

22 Ventilator-Associated Pneumonia
Rate 2.8 – 12.3 per 1000 ventilator days (NHSN 2006) 10-30% of intubated patients Incidence increases with duration of MV Day 1-5: 3% risk per day Day 6-10: 2% risk per day > 10 days: 1% risk per day Attributable mortality rate 33-50% Increased LOS 7-9 days Cost of $40,000 per patient Accounts for 50% of ICU antimicrobials Clinical vs. microbiologic definitions Poor external quality measure Am J Respir Crit Care Med 2005;171:

23 NHSN Mean VAP by Unit 2006-2008 Rate per 1000 vent-days
BICU: Burn PICU: Pediatric med/surg CICU: Coronary NICU: Neurosurgery CT ICU: Cardiothoracic SICU: Surgical MICU: Medical TICU: Trauma Am J Infect Control 2009;37:

24 “Ventilator Bundle” Head of bed elevation > 30 degrees*
Daily “sedation vacation” and assessment of readiness to extubate* Oral care (chlorhexidine) Peptic ulcer disease prophylaxis* Deep vein thrombosis prophylaxis* Reduction in VAP from 6.6 to 2.7 (59%) per 1000 ventilator-days with > 95% compliance (Jt Comm J Qual Patient Saf 2005;31(5):243-8) *Institute for Healthcare Improvement

25 Policy to Implementation
Daily compliance and weekly feedback Ventilator Bundle J Trauma 2006;61:

26 Which of the following has been demonstrated to reduce surgical site infections and is currently part of national recommendations? Peri-operative prophylactic antibiotics should be given within 60 minutes after incision Peri-operative prophylactic antibiotics should be given within 60 minutes before incision and discontinued within 24 hours Peri-operative antibiotics should be continued until the drains are out Nasal carriage of S. aureus should be eradicated prior to surgery Pre-surgical bath with chlorhexidine

27 Surgical Care Improvement Project
Implemented by CDC and Centers for Medicare and Medicaid Services in 2002 Nationally included procedures Cardiothoracic, vascular, colon, hip or knee arthroplasty, vaginal or abdominal hysterectomy Performance measures (Baseline of 34,133 medicare patients in 2001) Antimicrobial prophylaxis within 1 hr of incision (55.7%) Antimicrobial agent c/w current guidelines (92.6%) Discontinuation within 24 hours after surgery (40.7%) Role of MRSA screening? Arch Surg 2005;140:174-82

28 Perioperative Prophylactic Antibiotics Timing of Administration
14/369 15/441 1/41 1/47 Infections (%) 1/81 2/180 5/699 5/1009 Hours From Incision N Engl J Med 1992;326:281-6

29 Society of Thoracic Surgeons
Rationale Unique patient risks Cardiopulmonary bypass, systemic hypothermia Devastating sequelae of mediastinitis (7-20% mortality) No randomized studies < 48 hrs in CT surgery Major Recommendations Postoperative prophylactic antibiotics are given for 48 hours or less Duration not dependent on chest tube removal If risk for MRSA, then vancomycin AND cefazolin Routine mupirocin administration for all patients in the absence of documented negative testing for staphylococcal colonization Ann Thorac Surg 2006;81: Ann Thorac Surg 2006;83:

30 Is Vancomycin Alone Adequate?
Pathogens causing deep SSI following CABG, Hip and Knee Arthroplasty Acceptable for cardiac, vascular, or orthopedic surgery: Beta-lactam allergy Documented rationale NNIS

31 Meta-analysis of Seven Randomized Studies: Glycopeptide vs
Meta-analysis of Seven Randomized Studies: Glycopeptide vs. β-Lactam for Prevention of Surgical Site Infection after Cardiac Surgery MSSA more frequent in vancomycin group 3.7% vs. 1.3% (J Thorac Cardiovasc Surg 2002;123:326-32) Clin Infect Dis 2004;38:

32 Intranasal Mupirocin and Surgical Site Infections
Nasal carriage of S. aureus and risk of surgical site infection Orthopedic surgery with prosthetic implants in 272 patients, RR (Infect Control Hosp Epidemiol 2000;21: ) Cardiothoracic surgery in 1980 patients, OR (J Infect Dis 1995;171:216-9) 10/10 pre- and post-surgical pairs identical by phage typing Randomized, double-blind, placebo-controlled trial of pre-surgical mupirocin in 3864 patients (N Eng J Med 2002;346:1871-7) No difference in nosocomial infections, nosocomial S. aureus infections, or S. aureus surgical site infections S. aureus carriers (N=891) 4.5 fold increase in S. aureus SSI Significant reduction in S. aureus nosocomial infections (4.0 vs. 7.7) Trend towards decreased S. aureus SSI (3.7 vs. 5.9, 37%, P=0.15) Same strain in nares and site of infection in 85%

33 Universal Screening of Surgical Patients? JAMA 2008;299:1149-57
Prospective, cross-over study of 21,754 surgical patients 87% on admission MRSA colonization 5.1% Standard practices for all patients with MRSA Contact precautions Adjustment of pre-op prophylaxis Intranasal mupirocin and chlorhexidine body wash No difference in MRSA SSI (0.99 vs per 100) 34% of MRSA carriers did not receive appropriate pre-op prophylaxis None identified through outpatient screening developed MRSA infection

34 2% Chlorhexidine and 70% alcohol (Chloraprep) vs
2% Chlorhexidine and 70% alcohol (Chloraprep) vs. 10% Povidone Iodine for Surgical-Site Antisepsis Randomized, multi-center 849 patients Clean-contaminated surgery NNT: 17 patients N Engl J Med 2010;362:18-26

35 Pre-operative Chlorhexidine Baths
Cochrane Review of six randomized trials with 10,007 patients RR Chlorhexidine vs. placebo (0.80 to 1.04) Chlorhexidine vs. bar soap (0.57 to 1.84) Chlorhexidine vs. no washing (0.17 to 0.79) Cochrane Database Syst Rev Apr 18;(2):CD Review

36 It’s a small world… 26 y o medical student returns April 20, 2009 from an international elective in Mexico. On April 27 she presents to ED with 4 day h/o fever 39 C, cough, HA, myalgias, and diarrhea. That same day you hear reports of a novel Influenza A virus H1N1 associated with increased mortality in Mexico.

37 Which of the following is MOST correct regarding influenza?
No special precautions are necessary for patients with suspected influenza since it is not very transmissible. Influenza is primarily transmitted by large droplets (> 5 microns), therefore healthcare workers should use Droplet Precautions with a surgical mask with eye protection for routine care to prevent contamination of mouth, nose, and conjunctiva. Patients with 2009 H1N1 should be placed in airborne isolation with use of N-95 respirators while patients with H1N1 seasonal influenza should be placed in droplet precautions. A negative rapid antigen test rules out influenza Influenza vaccination of healthcare workers does not have an impact on patients.

38 Modes of Transmission Droplets Airborne Contact
Thought to be primary mode of transmission Coughing, sneezing, and talking Heavy; settle within 6 feet of the source Airborne Related to procedures → aerosolized particles Contact Direct: skin-to-skin contact Indirect: contact with virus in the environment 38

39 Respiratory Protection Debate
CDC (during influenza season) Fit-tested N95 respirators for care of patients with 2009 H1N1 Prioritized usage if limited resources Yet, Standard and Droplet Precautions for seasonal influenza? Infection Control and Infectious Diseases Societies* No evidence that 2009 H1N1 transmitted differently than seasonal influenza Standard and Droplet Precautions for routine care *Recommending organizations: World Health Organization (WHO) • Infectious Disease Society of America Healthcare Infection Control Practices • Society for Healthcare Epidemiology of America Advisory Committee (HICPAC) • Association of Professionals in Infection Control

40 Surgical Mask vs. N95 Respirator Randomized Study
Characteristic Surgical Mask N=212 N95 Respirator N=210 P Vaccinated 68 (30.2%) 62 (28.1%) Lab-confirmed* RT-PCR H1N1 serology Serology without symptoms 50 (23.6%) 6 (2.8%) 17 (8.0%) 29/44 (65.9%) 48 (22.9%) 4 (1.8%) 25 (11.9%) 31/44 (70.5%) 0.86 0.75 0.18 Physician visits 13 (6.1%) 13 (6.2%) 0.98 Influenza-like illness, Fever and cough 9 (4.2%) 2 (1.0) 0.06 Work-related absenteeism 42 (19.8%) 39 (18.6) *RT-PCR or serology JAMA 2009;302:

41 One Approach Standard, Droplet, and Contact Precautions for routine care Place mask on coughing patients Separate sick from non-sick patients Surgical mask, eye protection, gown, and gloves N95 respirators for higher-risk aerosol-generating procedures Intubation and extubation Bronchoscopy Open suctioning of airway Cardiopulmonary resuscitation Non-invasive ventilation? Suspected or Confirmed Cases of Influenza

42 43 y o woman from Eritrea with 3 week h/o non-productive cough, fever, and night sweats

43 Now What? AFB smear neg x (3 sputum, 2 BAL) Sputum AMTD neg

44 Which of the following is the BEST approach?
Remove from airborne isolation as a negative AMTD test rules out infectious TB Begin 4 drug therapy and remove patient from airborne isolation due to multiple negative AFB smears Begin 4 drug therapy and keep in airborne isolation Obtain interferon-gamma releasing assay (IGRA) as a negative result would rule out TB

45 44 y o Vietnamese man with 6 month h/o pain and swelling of left medial thigh associated with fevers and night sweats

46 Pulmonary Involvement in Extrapulmonary TB
• 72 patients with XPTB 36 lymph nodes 12 pleura 6 CNS 6 GI • 57 had sputum collection • Weight loss associated with positive sputum cx OR 4.3 ( ) 49% had abnormal CXR Chest 2008;134:589-94

47 Sputum AFB Smear Smear positive Smear negative, culture-positive TB
5,000-10,000 organisms per ml of sputum must be present Smear negative, culture-positive TB Responsible for roughly 17% of TB transmission in San Francisco and Vancouver 40-50% of pulmonary TB cases in King County are smear negative Am Rev Respir Dis 1966;95:998 Lancet 1999;353;444, Thorax 2004;59:286

48 Patient Safety and Infection Control
UW Medicine Strategic Goals Reduction in HAI Expectation of hand hygiene with EVERY patient EVERY the time WSHA elimination of HAI by 2012 Mandatory reporting of HAI CLA-BSI, VAP, selected surgical site infections MRSA legislation Increased linkage of reimbursement to quality CMS preventable “medical errors”


Download ppt "Healthcare-Associated Infections and Infection Control"

Similar presentations


Ads by Google